Evidence map›Paper›PMID 34917601›Full record

ArticleFrontiers in bioengineering and biotechnology2021

Evaluation of the Anti-Inflammatory and Anti-Oxidative Effects of Therapeutic Human Lactoferrin Fragments.

Yu Pan, Zhao Liu, Yijie Wang, Linshen Zhang, Niying Chua, Lei Dai, Jun Chen, Chun Loong Ho

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yu PanDepartment of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
Zhao LiuDepartment of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
Yijie WangDepartment of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
Linshen ZhangDepartment of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
Niying ChuaSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Lei DaiCAS Key Laboratory of Quantitative Engineering Biology, Chinese Academy of Sciences, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology (SIAT), Shenzhen, China.
Jun ChenDepartment of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
Chun Loong HoDepartment of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
Southern University of Science and Technology · CNNanyang Technological University · SGShenzhen Institutes of Advanced Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation is considered a pressing health issue that needs resolving. Inflammatory disease such as inflammatory bowel disease requires a long-term medical regimen to prevent disease progression. Conventionally, lactoferrin is used to treat mild gastrointestinal tract and skin inflammation. Protease-digested lactoferrin fragments often exhibit improved therapeutic properties compared to full-length lactoferrin (flHLF). However, there are no studies on the use of protease-digested lactoferrin fragments to treat inflammation. Herein, we assess the anti-inflammatory properties of engineered recombinant lactoferrin fragments (rtHLF4, rteHLF1, and rpHLF2) on non-malignant colonic fibroblast cells and colorectal cancer cells. We found that rtHLF4 is 10 times more effective to prevent inflammation compared to flHLF. These results were investigated by looking into the reactive oxygen species (ROS) production, angiogenesis activity, and cellular proliferation of the treated cells. We have demonstrated in this study the anti-inflammatory properties of the flHLF and the various lactoferrin fragments. These results complement the anti-cancer properties of these proteins that were demonstrated in an earlier study.

Indexed as

anti-infammatorylactoferrinnon-malignant colonic fibroblasts cellsprotease-digestedtNF-alpha

Identifiers

PMID34917601
PMCPMC8671034
OpenAlexW3217693815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.